Hidden Funding and Weak Evaluation Threaten CME Trust
Earlier coverage of accreditation operations and its implications for CME providers.
Declining commercial support and accelerating private-equity acquisitions are forcing CME providers into an explicit choice between short-term revenue stability and long-term educational independence.
Declining commercial support and accelerating private-equity acquisitions are forcing CME providers into an explicit choice between short-term revenue stability and long-term educational independence. A single provider-owned podcast narrated the full 1950s-to-2023 funding arc and tied today’s revenue mix to new operational questions; the evidence remains narrow but the decision points are concrete.
For earlier context, see CME Planning Now Requires Defining the Destination Before Choosing the Route.
The clearest point in Write Medicine’s episode, “Follow the Money: The Unexpected Economics of CME”, was that today’s revenue mix changes what providers must be able to prove.
The episode traced CME from a participant-fee and institution-supported model in the 1950s and 1960s, through a period when pharmaceutical support reached an estimated 50% to 65% of funding in the early 2000s, to a 2023 picture in which commercial support was described as about 24% of CME funding, with registration fees at about 54%. Stronger ACCME firewalls accompanied that shift.
For CME executives, independence can no longer be treated as a compliance layer added after the business model is set. Registration fees, exhibitor revenue, advertising, grants, donations, and institutional support each bring distinct pressure on pricing, access, content mix, and reporting.
That makes revenue architecture part of educational governance. A provider that depends heavily on one source may still be compliant but less resilient when budgets tighten or ownership changes. The same logic that requires defining accountability before designing activities now applies upstream to the business model.
The private equity thread sharpens the question. The episode described CME providers as attractive acquisition targets because they offer access to healthcare professionals and scalable education infrastructure, while warning that acquisition can bring staff reductions, standardization, and pressure for short-term returns. That is not proof of a field-wide pattern, but it is a useful board-level prompt.
The question for CME teams is not simply whether revenue can be diversified. It is which parts of the educational mission remain non-negotiable when revenue, ownership, or staffing assumptions change.
This narrow signal is less about private equity as a headline and more about readiness. If a provider’s independence story depends mainly on ACCME paperwork, it may be too thin for the next phase of funding pressure. The stronger position is to know, in advance, which revenue sources support the mission, which ones distort it, and which safeguards would still hold if the organization had to move faster, scale harder, or justify every program against near-term financial returns.
Narrates full historical arc from 1950s participant-fee model through 50-65% pharma peak to 2023 24% commercial / 54% registration split; explicitly flags PE acquisition risks including staff cuts, standardization pressure, and mission erosion.
Open sourceEarlier coverage of accreditation operations and its implications for CME providers.
Earlier coverage of accreditation operations and its implications for CME providers.
Earlier coverage of accreditation operations and its implications for CME providers.
ChatCME surfaces the questions clinicians actually ask — so you can build activities that close real knowledge gaps.
Request a demo